Sitagliptin: a novel agent for the management of type 2 diabetes mellitus (Q37102012)

18 August 2017

0 references

1 reference

title

Sitagliptin: a novel agent for the management of type 2 diabetes mellitus (English)

1 reference

18 August 2017

0 references

David Q Pham

1

1 reference

PubMed ID

18319497

18 August 2017

Anna Nogid

series ordinal

2

1 reference

PubMed ID

18319497

18 August 2017

Roda Plakogiannis

series ordinal

3

1 reference

18 August 2017

1 March 2008

1 reference

American Journal of Health-System Pharmacy

18 August 2017

1 reference

18 August 2017

65

1 reference

18 August 2017

6

1 reference

18 August 2017

521-531

1 reference

Diagnosis and classification of diabetes mellitus

18 August 2017

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070248

Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070248

The physiology of incretin hormones and the basis for DPP-4 inhibitors.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070248

The biology of incretin hormones

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070248

Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070248

Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070248

Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070248

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070248

Glucagon-like peptide (GLP)-1 and leptin concentrations in obese patients with Type 2 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070248

Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070248

Elevated plasma glucose-dependent insulinotropic polypeptide associates with hyperinsulinemia in impaired glucose tolerance

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070248

Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070248

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070248

Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070248

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070248

Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070248

Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070248

Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070248

Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070248

Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070248

Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070248

Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070248

Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070248

Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor AVE7688 in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070248

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070248

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070248

Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070248

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070248

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070248

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070248

Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070248

Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070248

Effect of a single cyclosporine dose on the single-dose pharmacokinetics of sitagliptin (MK-0431), a dipeptidyl peptidase-4 inhibitor, in healthy male subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070248

31 March 2020

Identifiers

DOI

10.2146/AJHP070248

1 reference

18 August 2017

1 reference

PubMed ID

18319497